Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGL Agilon Health	$1.24 -10.5%	$1.84	$0.71 ▼ $6.08	$511.81M	0.14	7.24 million shs	7.86 million shs
CSTL Castle Biosciences	$21.35 +3.8%	$18.77	$14.59 ▼ $35.84	$619.32M	1.09	475,762 shs	490,603 shs
DCGO DocGo	$1.65 +0.6%	$1.54	$1.23 ▼ $5.68	$161.39M	0.96	843,505 shs	299,104 shs
FLGT Fulgent Genetics	$21.47 -0.3%	$19.67	$14.57 ▼ $23.56	$657.20M	0.83	352,857 shs	255,958 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGL Agilon Health	+3.77%	+11.34%	-33.41%	-38.62%	-69.31%
CSTL Castle Biosciences	-1.30%	+0.05%	+28.00%	+30.19%	-30.44%
DCGO DocGo	-4.65%	-2.38%	+12.33%	+17.99%	-55.91%
FLGT Fulgent Genetics	-1.10%	+0.05%	+17.20%	+6.64%	-9.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGL Agilon Health	2.6226 of 5 stars	4.1	2.0	0.0	3.1	0.0	0.6
CSTL Castle Biosciences	2.4258 of 5 stars	3.5	3.0	0.0	2.7	1.7	0.0
DCGO DocGo	2.0806 of 5 stars	3.3	3.0	0.0	1.9	0.8	0.6
FLGT Fulgent Genetics	3.6439 of 5 stars	2.3	1.0	4.1	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGL Agilon Health	2.11	Hold	$3.07	148.70% Upside
CSTL Castle Biosciences	3.00	Buy	$37.00	73.30% Upside
DCGO DocGo	2.50	Moderate Buy	$3.59	117.58% Upside
FLGT Fulgent Genetics	2.67	Moderate Buy	$25.33	17.99% Upside

Current Analyst Ratings Breakdown

Latest DCGO, FLGT, CSTL, and AGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DCGO DocGo	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$1.45 ➝ $1.60
8/20/2025	AGL Agilon Health	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$4.00 ➝ $1.40
8/15/2025	AGL Agilon Health	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$2.40 ➝ $1.10
8/14/2025	AGL Agilon Health	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $1.00
8/6/2025	AGL Agilon Health	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$3.00 ➝ $1.50
8/6/2025	AGL Agilon Health	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $1.50
8/5/2025	FLGT Fulgent Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$20.00 ➝ $30.00
8/4/2025	FLGT Fulgent Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$23.00 ➝ $21.00
7/9/2025	AGL Agilon Health	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$5.00 ➝ $3.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGL Agilon Health	$5.90B	0.09	N/A	N/A	$1.14 per share	1.08
CSTL Castle Biosciences	$346.27M	1.79	$1.01 per share	21.18	$16.28 per share	1.31
DCGO DocGo	$616.55M	0.26	$0.41 per share	4.07	$3.09 per share	0.53
FLGT Fulgent Genetics	$283.47M	2.32	N/A	N/A	$36.92 per share	0.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGL Agilon Health	-$260.15M	-$0.77	N/A	N/A	N/A	-5.35%	-66.76%	-17.47%	11/6/2025 (Estimated)
CSTL Castle Biosciences	$18.25M	-$0.35	N/A	N/A	N/A	-2.73%	2.37%	2.03%	11/3/2025 (Estimated)
DCGO DocGo	$19.99M	-$0.19	N/A	20.63	N/A	-4.20%	-3.26%	-2.24%	11/6/2025 (Estimated)
FLGT Fulgent Genetics	-$42.71M	-$1.66	N/A	N/A	N/A	-16.83%	-2.26%	-2.10%	11/14/2025 (Estimated)

Latest DCGO, FLGT, CSTL, and AGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DCGO DocGo	-$0.06	-$0.11	-$0.05	-$0.11	$77.58 million	$80.42 million
8/4/2025	Q2 2025	AGL Agilon Health	-$0.11	-$0.25	-$0.14	-$0.25	$1.47 billion	$1.39 billion
8/4/2025	Q2 2025	CSTL Castle Biosciences	-$0.51	$0.15	+$0.66	$0.15	$71.53 million	$86.18 million
8/1/2025	Q2 2025	FLGT Fulgent Genetics	-$0.23	$0.07	+$0.30	-$0.62	$76.21 million	$81.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGL Agilon Health	$1.80	145.75%	N/A	N/A	N/A
CSTL Castle Biosciences	N/A	N/A	N/A	N/A	N/A
DCGO DocGo	N/A	N/A	N/A	N/A	N/A
FLGT Fulgent Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGL Agilon Health	N/A	1.16	1.16
CSTL Castle Biosciences	0.02	6.85	6.69
DCGO DocGo	N/A	2.36	2.36
FLGT Fulgent Genetics	N/A	6.01	6.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGL Agilon Health	N/A
CSTL Castle Biosciences	92.60%
DCGO DocGo	56.44%
FLGT Fulgent Genetics	48.06%

Insider Ownership

Company	Insider Ownership
AGL Agilon Health	3.57%
CSTL Castle Biosciences	6.50%
DCGO DocGo	3.80%
FLGT Fulgent Genetics	33.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGL Agilon Health	1,076	414.42 million	399.63 million	Not Optionable
CSTL Castle Biosciences	540	29.01 million	26.92 million	Optionable
DCGO DocGo	4,407	97.81 million	94.09 million	Optionable
FLGT Fulgent Genetics	1,313	30.61 million	20.47 million	Optionable

DCGO, FLGT, CSTL, and AGL Headlines

Recent News About These Companies

Fulgent Genetics, Inc. $FLGT Shares Bought by Deutsche Bank AG

August 19, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Increases Stock Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

August 15, 2025 | marketbeat.com

XTX Topco Ltd Takes $324,000 Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

August 11, 2025 | marketbeat.com

Fulgent Genetics (FLGT) Receives a Hold from Piper Sandler

August 9, 2025 | theglobeandmail.com

Fulgent Genetics (NASDAQ:FLGT) Shares Up 9.3% - Here's Why

August 6, 2025 | marketbeat.com

Fulgent Genetics (NASDAQ:FLGT) Raised to "Buy" at UBS Group

August 6, 2025 | marketbeat.com

UBS Upgrades Fulgent Genetics (FLGT)

August 6, 2025 | msn.com

Fulgent Genetics (NASDAQ:FLGT) Shares Down 3.4% Following Analyst Downgrade

August 5, 2025 | marketbeat.com

Fulgent Genetics (NASDAQ:FLGT) Price Target Lowered to $21.00 at Piper Sandler

August 5, 2025 | marketbeat.com

Fulgent Genetics’ Earnings Call Highlights Growth and Optimism

August 4, 2025 | theglobeandmail.com

Fulgent Genetics (NASDAQ:FLGT) Announces Quarterly Earnings Results

August 3, 2025 | marketbeat.com

Fulgent Genetics (NASDAQ:FLGT) Shares Gap Up After Earnings Beat

August 2, 2025 | marketbeat.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q2 2025 Earnings Call Transcript

August 2, 2025 | insidermonkey.com

Fulgent Genetics (NASDAQ:FLGT) Updates FY 2025 Earnings Guidance

August 2, 2025 | marketbeat.com

Fulgent (FLGT) Q2 Revenue Jumps 16%

August 2, 2025 | fool.com

Why Fulgent Genetics Stock Was Crushing It on Friday

August 1, 2025 | fool.com

Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript

August 1, 2025 | seekingalpha.com

Fulgent Genetics, Inc. 2025 Q2 - Results - Earnings Call Presentation

August 1, 2025 | seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates

August 1, 2025 | zacks.com

1FLGT : Fulgent Genetics Earnings Preview

July 31, 2025 | benzinga.com

Fulgent Genetics, Inc. (NASDAQ:FLGT) Shares Sold by Bank of New York Mellon Corp

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO, FLGT, CSTL, and AGL Company Descriptions

Agilon Health NYSE:AGL

$1.24 -0.15 (-10.51%)

Closing price 03:59 PM Eastern

Extended Trading

$1.24 0.00 (0.00%)

As of 05:12 PM Eastern

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.

Castle Biosciences NASDAQ:CSTL

$21.35 +0.78 (+3.79%)

Closing price 04:00 PM Eastern

Extended Trading

$21.36 +0.00 (+0.02%)

As of 04:10 PM Eastern

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

DocGo NASDAQ:DCGO

$1.65 +0.01 (+0.61%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 0.00 (-0.30%)

As of 04:10 PM Eastern

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.

Fulgent Genetics NASDAQ:FLGT

$21.47 -0.06 (-0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$21.48 +0.01 (+0.02%)

As of 04:31 PM Eastern

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time